Archive: "Personalized Medicine"

Pepscan announces research collaboration with Fusion Pharmaceuticals to discover and develop peptide-based radiopharmaceuticals

Juul Zwinkels News releases

Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced a strategic research collaboration with Fusion Pharmaceuticals to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Pepscan’s unique CLIPS™ phage display platform will screen billions of peptides to discover highly constrained de novo peptides with enhanced affinities, selectivities, and proteolytic stabilities. “We are pleased to partner with Pepscan, a global leader in peptide discovery with a platform that will enable us to create novel, …

Column purification technology expanded to guarantee short timelines and flexibility for (GMP) batches

Juul Zwinkels News releases

At Pepscan, we help you guide your peptide project through the various stages of development towards clinical application and commercialization. To support the growing number of customers looking for mid-sized batches of custom-made (GMP) peptides, Pepscan has extended our column purification technology with a mid-sized column packer. “This technology significantly reduces purification time compared to the methodology for smaller batch sizes,” explains Richard van Duinkerken, Purified Peptides team lead. “This new equipment ensures that we can keep providing our clients …

How the first effective peptide vaccine was developed at Pepscan

Juul Zwinkels News releases

Jan Langeveld (PhD) on how luck, international collaboration and “pur sang” research led to success. In 1990, Jan Langeveld joined forces with Rob Meloen, who later became Pepscan’s founder but at the time was working for the Institute for Animal Science and Health in Lelystad. For Langeveld, the Pepscan technique seemed a quick and cheap way to unravel antibody specificity, and represented a revolution in our understanding of protein structure and function. At the time, Meloen was also expecting progress …

How mastering peptides became Pepscan’s DNA

Juul Zwinkels News releases

Rob Meloen on how ingenuity and dedication became the core of Pepscan “The power of Pepscan has always been the people: incredibly smart, dedicated and ingenious. Not only in finding scientific solutions but also in operational areas. I believe it says it all that I used to say, ‘No more discoveries after Friday 3 o’clock’,” shares Rob Meloen, founder of Pepscan, with a smile on his face. “To develop new vaccines, therapeutics or diagnostic tools, you have to put a …

Pepscan celebrates 25th anniversary

Juul Zwinkels News releases

Pepscan celebrates its 25th anniversary. The company, founded by Professor Emeritus Rob Meloen in 1996, is now the all-in-one partner in peptides. Over the coming months, we will share stories from the last two-and-a-half decades, starting with our founder, who lay the basis for an important part of Pepscan’s DNA: mastering peptides. We will also highlight how Pepscan developed the first effective peptide vaccine. In 2022, we plan to host an event to toast to 25 years of mastering peptides. …

Pepscan joins Neoantigen Based Therapies Summit

Juul Zwinkels News releases

Cancer immunotherapies stimulate the immune system to (re)gain or enhance its ability to recognize cancer cells as foreign and inhibit their proliferation or kill them. This recognition and distinction from healthy cells can be achieved because cancer cells produce aberrant forms of a variety of proteins, some of which are presented on the cell surface as tumor antigens. Neoantigens are one type of cancer antigens that arise from point or frameshift mutations in the cancerous cells and are often unique …

Meet Pepscan at CPhI Worldwide 2021

Juul Zwinkels News releases

The Pepscan team is excited to meet you in person at the upcoming edition of CPhI Worldwide in Milan, Italy (November 9-11). We will be at booth 18J51 and would be happy to discuss how Pepscan combines smart peptide science and flexible manufacturing capabilities that conform to GMP. Over the last few years, we have made tremendous efforts and investments in building our GMP capabilities at our Dutch all-in-one facility. Starting from GMP production of neoantigen vaccines at microgram scale, …

Pepscan joins Biologics UK

Juul Zwinkels News releases

Meet us at Biologics UK in London! We’re very excited to attend our first in-person event in 2021 and to share our experience in clinically-applied radiopharmaceutical peptides. Visit us at our booth (4) or reach out to Zoran Medic to schedule an appointment or for more info.

Ardigen, ImmuMap and Pepscan kick-off collaboration for T-cell receptor discovery

Juul Zwinkels News releases

Ardigen. ImmuMap and Pepscan recently kicked off their collaboration. The research study, called Creating an innovative AI-based (artificial intelligence) in silico technology TCRact to launch a new service for designing and optimizing T-cell receptors (TCR) for use in cancer immunotherapies, is partly funded through a grant obtained by Ardigen from the EU’s European Regional Development Fund under the Intelligent Development Program.  The scope of the collaboration will revolve around the identification of T-cell receptors reactive towards newly identified neoantigens of …

Pepscan expands capacity at multiple gram scales to keep delivering optimal flexibility for its (GMP) customers

Juul Zwinkels News releases

Pepscan’s technicians recently installed and qualified a new fully automated two-liter peptide synthesizer enabling production of 10–30 gram batches. This new piece of equipment ensures Pepscan can keep providing its clients optimal flexibility when synthesizing peptides for their clinical or research purposes; it also allows Pepscan to meet the rapidly increasing demand from clients who need peptides in  an upscaling trajectory for their clinical trials. “In the past our peptide production capacity has at times bottlenecked, preventing us from delivering to …

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the Pepscan website. However, if you would like to, you can change your cookie settings at any time in your browser.
Cookie Policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies